Market research analysts at Technavio predict that the global short bowel syndrome (SBS) market will grow steadily at a CAGR of around 26% by 2021. This market research analysis identifies the special drug designations as one of the primary growth factors for this market. The market is dominated by few drugs and the special designation provides more potential for revenue generation and geographical expansion. The designation provides the vendors with benefits such as the extension of patent exclusivity period to address the need for an orphan drug, tax credits up to half of R&D costs, and exemption from US FDA application fees, consequently, reducing the vendors burden in developing a product for a rare disease. The R&D expenses are high for such novel molecules, as a result, a special designation encourages the vendors to conduct such R&D, which otherwise would make the molecule economically unviable.
The market research report identifies the increased awareness of gastrointestinal (GI) disorders as one of the key trends behind the growth of this market. Many government bodies, pharmaceutical companies, health ministries, and NGOs conduct health programs and camps to educate the people and raise awareness. Vendors distribute free samples and kits with the aim of educating the people and promoting their drugs. The increasing public awareness about the generic disorders or bowel related disorders is influencing the vendors and authorities to provide adequate knowledge and information to the segment with limited knowledge. The increasing awareness about the overall bowel health maintenance and remedial measures will benefit this niche market for SBS in terms of patient compliance and will increase sbs market revenue.
Competitive landscape and key vendors
The SBS market is dominated by few key players. To gain a competitive edge and improve their market shares, the vendors in the market are increasingly focusing on following strategies such as mergers and acquisitions and distribution through partnerships and are also concentrating on attending medical trade shows.
The leading vendors in the market are -
The other prominent vendors in the market are Ardelyx, Naia Pharmaceuticals, Nutrinia, OxThera, Sancilio Pharmaceuticals, and Zealand Pharma.
Segmentation by route of administration and analysis of the SBS market
During 2016, the parental route segment accounted for the major shares and dominated the SBS market. Factors such as the rapid action mechanism of the drug and the prolonged action result contribute to the growth of this market segment in the coming years. In the parental route, the drug is administered intravenously, subcutaneously, intrathecally, or through intramuscular routes and is applied when the oral route of drug administration is ineffective.
Segmentation by drug class and analysis of the SBS market
Glucagon-like peptide-2 (GLP-2)
During 2016, the SBS market was dominated by the GLP-2 segment. This drug class improves intestinal absorption of fluids and nutrients, thereby reducing the frequency and volume of PN, consequently being the most recommended drugs for short bowel syndrome. Factors such as the ability to induce adaption after resection and intestinotrophic growth will fuel the growth of this market segment.
Key questions answered in the report include
What will the market size and the growth rate be in 2021?
What are the key factors driving the global short bowel syndrome market?
What are the key market trends impacting the growth of the global short bowel syndrome market?
What are the challenges to market growth?
Who are the key vendors in the global short bowel syndrome market?
What are the market opportunities and threats faced by the vendors in the global short bowel syndrome market?
Trending factors influencing the market shares of the Americas, APAC, and EMEA.
What are the key outcomes of the five forces analysis of the global short bowel syndrome market?
Technavio also offers customization on reports based on specific client requirement.